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ABSTRACT: Bifunctional molecules known as PROTACs simultaneously bind an E3 ligase and 
a protein of interest to direct ubiquitination and clearance of that protein, and have 
emerged in the last decade as an exciting new paradigm in drug discovery.  In order to 
investigate the permeability and properties of these large molecules, we synthesised two 
panels of PROTAC molecules, constructed from a range of protein-target ligands, linkers and 
E3 ligase ligands. The androgen receptor, which is a well-studied protein in the PROTAC field 
was used as a model system.  The physicochemical properties and permeability of PROTACs 
is discussed. 
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Chemically-induced, targeted protein degradation is an emerging pharmacological strategy for 
manipulation of intracellular protein levels.1 One way this has been achieved is through the 
design of bifunctional molecules that simultaneously bind to a protein of interest and an E3 
ubiquitin ligase. By bringing these two proteins into proximity, PROteolysis TArgeting Chimeras 
(PROTACs) facilitate the ubiquitinylation and proteasomal degradation of the protein of 
interest. Early PROTACs relied on short peptide sequences to bind the E3 ligase protein and 
their low permeability necessitated microinjection into cells,2 however recent identification 
of small molecule ligands for E3 ligases has opened the possibility of cell-permeable non-
peptidic PROTACs.  The ability to degrade the entire protein in a cell, rather than simply inhibit 
the catalytic domain, distinguishes PROTACs from traditional small-molecule inhibitors.  
Further, the removal of additional roles of the protein, such as complex formation and 
scaffolding with other proteins, means that PROTACs can access unique pharmacology.  
PROTACs are also potentially catalytic, each molecule can direct degradation of multiple target 
proteins.  PROTACs have been developed for numerous protein classes, including nuclear 
receptors,3 epigenetic factors,4 and kinases.5 These compounds have been used to study the 
effect of enforced degradation of the target protein in a number of cell lines and also in in vivo 
studies.6, 7 Whilst this work has the potential to offer a new pharmacological paradigm, clinical 
utility is yet to be demonstrated and a number of challenges still remain.8  A recent in vivo 
study of a potent PROTAC (DC50 0.3 nM) indicated that despite an impressive systemic knock-
down of the desired FKBP12 protein, the brain was the only tissue analysed where protein 
levels were unaffected, indicating that the blood-brain barrier may intrinsically present a 
greater challenge to PROTACs than other biological membranes.7 
PROTAC molecules are rule-breaking in respect to traditional medicinal chemistry guidelines8; 
they possess high molecular weight and high TPSA.9 Permeability is key for activity against 
intracellular targets and in general, permeability drops off drastically with increasing 
molecular weight yet despite this, some impressive cell potencies for PROTACs have been 
reported.6 Other classes of small-molecules, also beyond the rule of 5, have been reported to 
have high cell permeability and oral bioavailability.10 Notably, cyclic peptides and natural 
products such as rifamycins are thought to adopt conformations that allow formation of 
intramolecular hydrogen bonds, reducing the effective polarity of the molecules and allowing 
passage through membranes.11, 12  We hypothesised that in a similar fashion, it might be 
possible for PROTAC molecules to possess rule-breaking permeability, either by linker-
mediated conformational collapse in water, or by the two functional ends of the PROTAC 
migrating through a membrane in a pseudo-independent fashion by virtue of the length and 
flexibility of the linker so disguising their high molecular volume.  PROTAC molecules are 
typically composed of two rigid protein-binding small molecules, connected by a linker. As we 
focus on flexible linkers in this work, further linker types with more rigidity remain to be 
explored. Recently Foley et al have published observations on permeability using a 
chloroalkane penetration assay, focusing on the permeability of a chloroalkane modified BRD4 
PROTAC.13  A wider study to evaluate the impact of linker, protein-ligand and E3 ligase ligand 
on the permeability of PROTACs is warranted.   
In our study, the androgen receptor (AR) was selected as a model system.  A panel of selective 
AR modulators (SARMs) have previously been developed, and many PROTACs for the AR 
protein have also been reported, employing a variety of E3 ligase ligands.2, 3, 14, 15  As such it is 
a de-risked, well-studied system.  The AR is a DNA-binding transcription factor nuclear 
hormone receptor that, through binding to the endogenous ligand testosterone, mediates 
growth factor and cell-signalling dependent gene expression. The ligand binding domain (LBD) 
provides a defined binding pocket for endogenous steroidal ligands including testosterone. A 
number of SARMs are in clinical trials for a variety of indications.14, 16 Furthermore, 
polyglutamine expansion of the AR causes the neuromuscular disease spinal and bulbar 
muscular atrophy (SBMA or Kennedy’s disease).17 A PROTAC designed to catalyse the 
degradation of this neurotoxic form of AR could offer a strategy for intervention in this disease. 
 
Figure 1: (A) AR ligand 2 in complex with AR ligand binding domain (pdb id: 3v49).  The linker attachment point is circled in 
red. (B) Structures of compounds 1-5, derived from AR ligands, for incorporation into PROTACs.  The linker attachment point 
is indicated in red. (C) Proteolysis directing groups 6-9, the attachment point when incorporated into PROTACs is indicated 
in blue. (D) Lenalidomide bound to Cereblon E3 ubiquitin ligase (pdb id: 4ci2).  The linker attachment point is circled in blue. 
(E) General AR PROTAC structure of PROTAC Sets 1 and 2. 
 
In designing a set of PROTACs, the three components of the PROTAC molecule were 
systematically varied; the AR ligand, the E3 ubiquitin ligase ligand and the linker region. To 
select suitable ligands for the AR, SARMs were identified that were predicted to have good 
CNS permeability using MPO scoring.18 SARMs 1-5 all bind in the LBD of the AR, Figure 1A.  An 
analysis of the binding modes of available crystal structures reveals SARMs present a similar 
vector to exit the AR binding site, in a position that has been successfully exploited by 
previously reported AR PROTACs.3 The structures of AR ligands 1-5 are shown in Figure 1B.  
SARM 1 is a close analogue of the clinical compounds andarine and ostarine. The hydantoin 
SARM 2 possesses high affinity for AR (EC50 1.6 nM).19 The thiohydantoin derivative 3 has been 
developed into the clinical compound enzalutamide, and incorporated into PROTACs.20  
Pyrrolidine-based SARM 4 represents a very ligand-efficient class of modulators, of which 
Ligandrol is a compound in clinical development.21 The cyclobutane SARM 5 has also been 
previously reported.22 
X-ray crystal structures of SARMs bound to AR reveal the ligand completely enclosed by helix 
12 (Figure 2A).  In order for AR PROTACs to bind and the linker to exit the AR protein, some 
protein conformational change must occur.  Gryder et al. have previously reported a set of AR-
binding bifunctional molecules that also bind histone deacetylases (HDAC), and suggests that 
helix 12 (H12) forms a ‘lid’ over SARMs, that can move to accommodate extended AR ligands.23  
Indeed, the related estrogen receptor (ER) demonstrates large changes in the conformation 
of H12 when bound to an antagonist,24 hence we created a homology model of the AR with 
an H12-open conformation, based upon an H12-open ER protein complex (Figure 2B and 
Supporting Information).  Docking PROTACs into this model successfully reproduced the 
binding mode of the SARM, and allowed the linker to extend past H12 into the solvent, 
permitting a rational design of linker length and linker-SARM attachment points. 
 
Figure 2 (A) Helix 12 (H12, red) of AR protein (pdb id: 2pnu) occludes the entrance to the ligand-binding domain.  The docked 
small molecule 3b (Figure S1) is indicated by green spheres.  (B) A homology model of AR with helix-12 in an open 
conformation (red helix) was generated.  The re-modelled helix 12 allows access from the ligand-binding domain to the bulk 
solvent, and accommodation of PROTAC linkers. 
Only a limited number of E3 ligases have been targeted by PROTAC molecules, though recent 
studies have focused on expanding the repertoire.25 We employed 4 different proteolysis 
targeting groups 6-9, with distinct physicochemical properties (Figure 1C). The 
immunomodulatory drugs thalidomide, and analogues pomalidamide and lenalidomide, have 
been identified as ligands of the E3 ligase Cereblon (Figure 1D), and structural analogues 6 
and 7 have been successfully incorporated into PROTACs.26 Small-molecule ligands of the von 
Hippel Lindau (VHL) E3 ligase such as 9, have also been developed and incorporated into 
PROTACs.4-6 Another approach to chemically target protein degradation has been to 
covalently27 or non-covalently28 associate a hydrophobic tag with a protein and thus promote 
its clearance.  It has been suggested in the context of AR clearance, that the presentation of 
the hydrophobic adamantane moiety 8 on the AR surface is recognised as unfolded protein by 
the Hsp70/CHIP system, leading to AR clearance.28 
For the first half of this work, a focused set of PROTACs (PROTAC Set 1, Figure 1E and S2) was 
synthesised by linking AR ligands and smaller E3 ligands with a PEG linker (10-19, Scheme S3 
and S4), predicted by calculations to have a neutral effect on the logD (Figure S4).  In the 
second half of the study, a further set of compounds (PROTAC Set 2, Figure 1E and S3) focused 
on the VHL E3 ligase was synthesised (20a-i, Scheme S6). In this set, the linker composition 
was varied to evaluate the impact of linker of permeability and functional activity.  Fluorine 
was also incorporated into the linker, which has not been reported in PROTAC linkers 
previously.  The effects of addition of fluorine may be wide-ranging, potentially altering 
properties such as the electrostatics of the linker, interaction with proteins, linker 
conformation,29 permeability and microsomal stability.  All PROTAC structures are shown in 
full in the SI (Figure S2 and S3). 
 
Figure 3: Structure, biophysical properties and biological activities of PEG-linked PROTAC Set 1. Coloring is added to aid 
visualization. (a) The general structure of a set of PROTACs (10-19, Set 1) is shown in the top left, comprised of AR ligands 1-
4, E3 ligase ligands 6-8 and a PEG-linker.  The PAMPA permeability for compounds 1-4 and 6-8 are shown in the outer edge 
of the table.  The main body of the table shows the PROTAC compound number in bold (10-19), composed from AR ligand 1-
4 and E3 ligase ligand 6-8, followed by PAMPA permeability. The same table format is used in (b)-(d). BLQ = Below limit of 
quantification (b) HSA % free determined by HPLC and as described in methods section (c) chromLogD7.4 determined by HPLC 
as described in methods section. 
With both sets of PROTACs in hand, the PEG-linked PROTACs (Set 1: 10-19, Figure 3) and the 
linker-varied VHL set (Set 2: 20a-I, Table 2), a panel of ADMET parameters was selected for 
their potential to impact cell activity; passive permeability (PAMPA), human serum albumin 
(HSA) binding and chromLogD7.4.  PROTACs 10-19 (Set 1, Figure 3) represent a model set of 
PROTACs with physicochemical properties that minimise molecular weight and TPSA and are 
not atypical to other PROTACs in terms of these parameters.  The chosen AR ligands are small 
and potent, the E3 ligase ligands have low molecular weight and the PEG-linker represents a 
typical reasonable linker length and distribution of polar atoms.3, 22  The PAMPA Papp for the 
AR ligands gives a wide range of permeability; low for ligand 1 (1.4 x 10-6 cm s-1) and high for 
ligand 4 (13.3 x 10-6 cm s-1) (Figure 3A).  Given the reported activity of PROTACs in the 
literature, reasonable permeability for this PROTAC set might be expected, especially when 
combining the most permeable AR ligand and E3 ligase ligand.  However, almost without 
exception, the permeability of the final PROTAC molecules in the PAMPA assay was very low 
and below the limit of quantification (Figure 3A and Table 2).  It is apparent that the high 
molecular weight and high TPSA, which is intrinsic to PROTAC molecules, is driving poor 
permeability for this class of molecules in this assay.  Recovery in the PAMPA assay was 
moderate, i.e. 40-80% in most cases (Table S2).  Of note is PROTAC 19, which combines 
ligandrol derivative 4 and adamantyl degron 8, and has a PAMPA permeability of 2.3 x 10-6 
cm s-1, the highest PAMPA permeability measured for our bifunctional molecules (Figure 3C).  
The high logD for this PROTAC, a feature of PROTACs with the lipophilic adamantyl head-
group, presumably contributes to the moderate permeability. 
Given the low passive permeabilities measured in the PAMPA assay, we also tested a selection 
of PROTAC molecules for bidirectional permeability in Caco-2 cells (Table 1 and Table 2).  
Briefly, this more biologically relevant assay uses a polarised monolayer of Caco-2 cells and 
hence allows assessment of permeability in two opposing directions (‘A2B’ and ‘B2A’), also 
permitting an assessment of active transport from the ratio of directional permeabilities.30 
Typical thresholds for permeability classification are; low < 1.0 x 10-6 cm s-1, medium 1-5 x 10-
6 cm s-1, high > 5 x 10-6 cm s-1.31 Whilst Caco-2 permeability is a useful measurement, in 
particular to predict oral bioavailability, inference of efflux ratios in other cell types may be 
complicated by different transporter profiles in different cell types.32 
 













aPermeability / 10-6 cm s-1; b Efflux Ratio. 
 
From the Caco-2 data it is possible to make comparisons to discern the effect of the E3 ligase 
ligand in the context of AR ligand 3 and a PEG-linker (Table 1).  Interestingly, cereblon ligand-
containing PROTAC 14 has the best A2B permeability measured at 1.7 x 10-6 cm s-1.  The B2A 
rate is high for this compound, 14.1 x 10-6 cm s-1, clearly indicating that transporter efflux is 
an issue (efflux ratio = 8.4).  Replacing the cereblon ligand with the small, hydrophobic 
adamantane degron in PROTAC 18 leads to a 10-fold decrease in A2B and a 64-fold decrease 
in B2A (0.15 and 0.22 x 10-6 cm s-1 respectively) and no evidence of transporter efflux (ER = 
1.5).  Substituting with the larger, more polar VHL ligand in PROTAC 20d gives an A2B 
permeability below the limit of quantification for this compound, but as the B2A rate is 9.6 x 
10-6 cm s-1, it is evident that an efflux issue is present (ER > 12).   
The effect of the linker on Caco-2 permeability was explored with a set of PROTACs from Set 
2 (VHL ligand containing PROTACs) (Table 2). For the PROTACs studied, A2B could either be 
quantified as low (<1.0 x 10-6 cm s-1), or couldn’t be measured at all.  Interestingly, a range of 









< 1.0 1.7 14.1 8.4 
18 
 
< 1.0 0.15 0.22 1.5 
20d 
 
< 1.0 < 0.69 8.6 > 12 
B2A rates were observed.  For PROTAC 20b, A2B and B2A were measured as 0.35 and 0.24 x 
10-6 cm s-1 respectively, indicating no significant transporter efflux.  It is noteworthy that the 
linkers of PROTACs 20b, 20c and 20g bearing different numbers of fluorine atoms lead to 
PROTACs that are all rather similar in terms of permeability; A2B and B2A rates are low.  
Contrastingly, PROTAC 20d demonstrates a high sensitivity to the change to a PEG-linker, B2A 
is high (8.6 x 10-6 cm s-1) and the efflux ratio is high (> 12).  In summary, low passive 
permeability in PAMPA assays is typically observed for PROTACs, but a marked structural 
influence of the linker and E3 ligase ligand on A2B, B2A and efflux ratio in Caco-2 cells can be 
observed.  The recovery of compounds in the Caco-2 assay was reasonable, 60-100% (Table 
S3).  Of note, all PROTACs were relatively unbound to HSA protein, between 6-15% (Figure 3B 
and Table 2).  More work is required to investigate this beyond the compound set studied 
here.  
 
Table 2: Structure, biophysical properties and permeability of VHL-targeting PROTACs (PROTAC Set 2). 
 
 









10% 6.0 < 1.0 < 2.7 1.4 > 0.5 
20b22 
 
9% 6.3 < 1.0 0.35 0.24 0.7 
20c 
 
7% 6.3 < 1.0 0.26 < 0.79 < 3 
20d 
 
11% 5.1 < 1.0 < 0.69 8.6 > 12 
20e22 
 
7% 6.2 < 1.0 ND ND ND 
20f 
 
6% 6.1 < 1.0 ND ND ND 
20g 
 
7% 6.1 < 1.0 < 0.11 0.33 > 3 
a HSA % free, determined by HPLC method; b chromLogD7.4, determined by HPLC method; c PAMPA permeability / 10-6 cm 
s-1; d Permeability / 10-6 cm s-1; e Efflux Ratio. ND = Not determined. 
The biological efficacy of the PROTACs to degrade endogenous levels of the AR receptor was 
assessed using a Western blotting technique in LNCaP cells.  LNCaP (androgen-dependent 
human prostate adenocarcinoma) cells are a well-characterised model for AR expression and 
are commonly used in AR PROTAC studies.  For effective clearance, a stable tertiary complex 
must form and surface lysines on the target protein must be presented in the correct manner 
for efficient ubiquitin transfer.25  Briefly, PROTAC activities can generally be described by two 
numbers; DCMAX is the percentage of protein clearance observed, and the DC50 is the 
concentration required to clear half of the DCMAX.  Previously reported22 PROTAC 20a was 
chosen as a positive control for the clearance assay, Figure 4A.  In general our PROTACs 
displayed mostly weak (DCMAX < 30%) or no clearance effects in the cell assay (not shown).  To 
disperse the concern that the generally poor activity observed in cells might be due to the 
chosen attachment points in the PROTACs preventing AR binding, representative PROTACs 
20a and 20i were tested for AR binding using a radioligand displacement assay (Figure S5).  
Both PROTACs retained low nM affinity for the androgen receptor, despite the different AR 
ligands, different linker and the attachment of the VHL ligand.  This is supportive of our 
docking model (Figure 2B), and indicates that the phenolic attachment point of the AR ligands 
in our PROTACs is compatible with AR binding in vitro.  The amide attachment point of the 
VHL ligand has been well validated in other PROTAC studies. 4-6   
 
The activity data for two structurally related PROTACs, 14 and 15, are shown in Figure 4B and 
serve to exemplify how small changes in PROTACs can lead to profound changes in cell 
activity.  PROTAC 15 is active (DCMAX = 33%, DC50 = 10 nM), but PROTAC 14 is inactive, despite 
possessing the highest A2B permeability measured, albeit with a high efflux ratio.  The only 
structural difference between the two PROTACs is whether the E3 ligase ligand possesses a 
carbonyl group in the cereblon-binding moiety.  Interestingly, Wang et al. have reported 
similar large activity differences regarding this carbonyl group in a set of BET PROTACs.33  
There are many reasons why PROTAC AR activity data may show idiosyncratic SAR, beyond 
permeability.  In particular, recent papers demonstrate that in the case of cereblon-binding 
PROTACs, small changes in PROTAC chemical structure can significantly reduce the intended 
activity of a bona fide PROTAC, and induce off-target GSPT1 degradation, thereby altering the 
PROTAC’s mode of action.34   
 









8% 5.8 < 1.0 ND ND ND 
20i22 
 
7% 6.7 < 1.0 ND ND ND 
 
Figure 4 (A) AR clearance activity of previously reported22 PROTAC 20a (B) AR clearance 
activity of PROTAC 14 and 15. Plots show normalised AR protein levels as a function of PROTAC 
concentration. PROTAC 14 is inactive in this cell assay.  A minor change of the Cereblon ligand 
leads to higher activity of PROTAC 15; a DCMAX of 33% and a DC50 of 10 nM. N=5 (or more) 
independent experiments performed in triplicate (individual data points shown). Statistical 
significance by ANOVA (Dunnett’s) **** = p<0.0001. 
 
In summary, even our simplest PROTAC molecules formed from moderately sized linkers 
connecting relatively small AR ligands and E3 ligase ligands possess low PAMPA and Caco-2 
A2B permeability.  If this is a general observation, it is clear that PROTAC permeability, is not 
“rule-breaking”.  Caco-2 permeability data sheds a little more light on the permeability profiles 
of some PROTACs and evidence of structure-dependent engagement with transport efflux 
proteins is observed.  We recommend that Caco-2 permeability therefore, rather than PAMPA 
permeability, might be a more useful measurement.  A recent publication from Cantrill et al. 
supports these conclusions.35  Broadly, a catalytic mode of action is supported by our 
permeability dataset, that sub-stoichiometric levels of PROTACs in a cell can catalyse the 
clearance of a target protein population.  Some minimal permeability threshold for PROTACs 
may exist, but is likely to be much lower than is usually recognised for Rule of 5-compliant 
small molecules.  The chemical stability of a PROTAC in a cell over time will also be important 
for the continued degradation of protein.  Recently, methodology to measure concentrations 
of small molecules in cellular compartments has become increasingly utilised and has already 
been applied to PROTACs.36  The use of this technology has emerged as a potentially useful 
tool to provide insights into PROTAC uptake into cells, though interpretation might be 
complicated by compound adhering to the outer cell membrane.  To investigate the real time 
clearance of proteins, Riching et al. have recently reported methods to monitor PROTAC-
induced protein degradation.37  Understanding the cellular uptake of a PROTAC, its stability in 
the cell over time, and the kinetics of protein clearance will be critical in informing design of 
better PROTACs.  By better understanding the connection between PROTAC structure and 
cellular efficacy, we will be able to rationally design better molecules and translate PROTAC 
molecules into the clinic more efficiently. 
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